These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8243628)

  • 1. Azidobutyryl clentiazem, a new photoactivatable diltiazem analog, labels benzothiazepine binding sites in the alpha 1 subunit of the skeletal muscle calcium channel.
    Watanabe T; Kalasz H; Yabana H; Kuniyasu A; Mershon J; Itagaki K; Vaghy PL; Naito K; Nakayama H; Schwartz A
    FEBS Lett; 1993 Nov; 334(3):261-4. PubMed ID: 8243628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photoaffinity labeling of the purified skeletal muscle calcium antagonist receptor by a novel benzothiazepine, [3H]azidobutyryl diltiazem.
    Naito K; McKenna E; Schwartz A; Vaghy PL
    J Biol Chem; 1989 Dec; 264(35):21211-4. PubMed ID: 2556399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-affinity binding of DTZ323, a novel derivative of diltiazem, to rabbit skeletal muscle L-type Ca++ channels.
    Hagiwara M; Adachi-Akahane S; Nagao T
    J Pharmacol Exp Ther; 1997 Apr; 281(1):173-9. PubMed ID: 9103495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding characteristics of a new 1,5-benzothiazepine, clentiazem, to rat cerebral cortex and skeletal muscle membranes.
    Suzuki T; Kurosawa H; Naito K; Otsuka M; Ohashi M; Takaiti O
    Eur J Pharmacol; 1991 Mar; 194(2-3):195-200. PubMed ID: 2060600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the benzothiazepine-binding polypeptide of skeletal muscle calcium channels with (+)-cis-azidodiltiazem and anti-ligand antibodies.
    Striessnig J; Scheffauer F; Mitterdorfer J; Schirmer M; Glossmann H
    J Biol Chem; 1990 Jan; 265(1):363-70. PubMed ID: 2152924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive heterotropic allosteric regulators of dihydropyridine binding increase the Ca2+ affinity of the L-type Ca2+ channel. Stereoselective reversal by the novel Ca2+ antagonist BM 20.1140.
    Staudinger R; Knaus HG; Glossmann H
    J Biol Chem; 1991 Jun; 266(17):10787-95. PubMed ID: 1645709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a phenylalkylamine binding region within the alpha 1 subunit of skeletal muscle Ca2+ channels.
    Striessnig J; Glossmann H; Catterall WA
    Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9108-12. PubMed ID: 2174553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydropyridine receptor of L-type Ca2+ channels: identification of binding domains for [3H](+)-PN200-110 and [3H]azidopine within the alpha 1 subunit.
    Striessnig J; Murphy BJ; Catterall WA
    Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10769-73. PubMed ID: 1660150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diazipine, a novel photoaffinity probe for dihydropyridine receptors of calcium channels.
    Taki M; Nakayama H; Kanaoka Y
    FEBS Lett; 1991 Jun; 283(2):259-62. PubMed ID: 1646123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of anandamide and arachidonic acid on specific binding of (+) -PN200-110, diltiazem and (-) -desmethoxyverapamil to L-type Ca2+ channel.
    Shimasue K; Urushidani T; Hagiwara M; Nagao T
    Eur J Pharmacol; 1996 Feb; 296(3):347-50. PubMed ID: 8904088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-affinity binding of [3H]DTZ323 to the diltiazem-binding site of L-type Ca2+ channels.
    Hagiwara M; Adachi-Akahane S; Nagao T
    Eur J Pharmacol; 2003 Apr; 466(1-2):63-71. PubMed ID: 12679142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and photoaffinity labeling of receptor sites for the Ca2+ channel inhibitors d-cis-diltiazem, (+/-)-bepridil, desmethoxyverapamil, and (+)-PN 200-110 in skeletal muscle transverse tubule membranes.
    Galizzi JP; Borsotto M; Barhanin J; Fosset M; Lazdunski M
    J Biol Chem; 1986 Jan; 261(3):1393-7. PubMed ID: 3003067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium channels: basic properties as revealed by radioligand binding studies.
    Glossmann H; Ferry DR; Goll A; Striessnig J; Schober M
    J Cardiovasc Pharmacol; 1985; 7 Suppl 6():S20-30. PubMed ID: 2414589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin binds with high affinity to voltage-dependent L-type Ca2+ channels. Evidence for an agonistic action.
    Knaus HG; Scheffauer F; Romanin C; Schindler HG; Glossmann H
    J Biol Chem; 1990 Jul; 265(19):11156-66. PubMed ID: 2162834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Ca2+ antagonists binding protein from cytosolic fraction the precursor of alpha 1-subunit of Ca2+ channel?
    Krizanová O; Hudecová S; Orlický J; Zachar J
    Gen Physiol Biophys; 1989 Apr; 8(2):99-111. PubMed ID: 2550315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of binding sites for calcium channel antagonists.
    Nakayama H; Kuniyasu A
    Jpn Heart J; 1996 Sep; 37(5):643-50. PubMed ID: 8973377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The devapamil-binding site of the purified skeletal muscle receptor for organic-calcium channel blockers is modulated by micromolar and millimolar concentrations of Ca2+.
    Schneider T; Regulla S; Hofmann F
    Eur J Biochem; 1991 Aug; 200(1):245-53. PubMed ID: 1652439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Ca++ on [3H]diltiazem binding and its allosteric interaction with dihydropyridine calcium channel binding sites in the rat cortex.
    Schoemaker H; Langer SZ
    J Pharmacol Exp Ther; 1989 Feb; 248(2):710-5. PubMed ID: 2537412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric interaction of semotiadil fumarate, a novel benzothiazine, with 1,4-dihydropyridines, phenylalkylamines, and 1,5-benzothiazepines at the Ca(2+)-channel antagonist binding sites in canine skeletal muscle membranes.
    Nakayama K; Nozawa Y; Fukuta Y
    J Cardiovasc Pharmacol; 1994 May; 23(5):731-40. PubMed ID: 7521455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SR 33557, a novel calcium entry blocker. II. Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes.
    Nokin P; Clinet M; Beaufort P; Meysmans L; Laruel R; Chatelain P
    J Pharmacol Exp Ther; 1990 Nov; 255(2):600-7. PubMed ID: 2147036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.